Catalyst Pharmaceuticals to Participate at the Barclays 26th Annual Global Healthcare Conference
March 05 2024 - 8:03AM
Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company")
(Nasdaq: CPRX), a commercial-stage biopharmaceutical company
focused on in-licensing, developing, and commercializing novel
medicines for patients living with rare and difficult to treat
diseases, today announced that Richard J. Daly, CEO of
Catalyst, along with other members of Catalyst's management team,
will participate at the upcoming Barclays 26th Annual Global
Healthcare Conference being held in Miami on March 12-14, 2024.
Participation Details:
Date: Tuesday,
March 12, 2024Format: Catalyst's management will
host 1x1 meetings and a fireside discussion at 1:35 pm ET.
A live webcast of the fireside will be available
on the Company's website, and a replay will be accessible
for at least 14 days.
About Catalyst Pharmaceuticals,
Inc.With exceptional patient focus, Catalyst is committed
to developing and commercializing innovative first-in-class
medicines that address rare and difficult-to-treat diseases.
Catalyst's flagship U.S. commercial product is
FIRDAPSE® (amifampridine) Tablets 10 mg, approved for the
treatment of Lambert-Eaton myasthenic syndrome ("LEMS") for adults
and for children ages six to seventeen. In January 2023,
Catalyst acquired the U.S. commercial rights to
FYCOMPA® (perampanel) CIII, a prescription medicine approved
in people with epilepsy aged four and older alone or with other
medicines to treat partial-onset seizures with or without
secondarily generalized seizures and with other medicines to treat
primary generalized tonic-clonic seizures for people with epilepsy
aged 12 and older. Further, Canada's national healthcare
regulatory agency, Health Canada, has approved the use of
FIRDAPSE for the treatment of adult patients
in Canada with LEMS. Finally, on July 18, 2023,
Catalyst acquired an exclusive license for North
America for AGAMREE® (vamorolone) oral suspension 40 mg/mL, a
novel corticosteroid treatment for Duchenne Muscular
Dystrophy. AGAMREE previously received FDA Orphan Drug and
Fast Track designations and was approved by the FDA for
commercialization in the U.S. on October 26, 2023.
For more information about Catalyst
Pharmaceuticals, Inc., visit the Company's website
at www.catalystpharma.com. For Full Prescribing and Safety
Information for FIRDAPSE®, visit www.firdapse.com. For Full
Prescribing Information, including Boxed WARNING for FYCOMPA®,
please visit www.fycompa.com. For Full Prescribing Information
for AGAMREE, please visit https://www.agamree.com.
Forward-Looking StatementsThis
press release contains forward-looking statements, as that term is
defined in the Private Securities Litigation Reform Act of 1995.
These include statements regarding Catalyst's expectations,
beliefs, plans, or objectives regarding the intended use of net
proceeds therefrom. Forward-looking statements involve known and
unknown risks and uncertainties, which may cause Catalyst's actual
results in future periods to differ materially from forecasted
results. A number of factors, including those factors described in
Catalyst's Annual Report on Form 10-K for the fiscal year 2023 and
its other filings with the U.S. Securities and Exchange
Commission ("SEC"), could adversely affect Catalyst. Copies of
Catalyst's filings with the SEC are available from
the SEC, may be found on Catalyst's website, or may be
obtained upon request from Catalyst. Catalyst does not undertake
any obligation to update the information contained herein, which
speaks only as of this date.
Source: Catalyst Pharmaceuticals, Inc.
Investor Contact
Mary Coleman, Catalyst Pharmaceuticals, Inc.
(305) 420-3200
mcoleman@catalystpharma.com
Media Contact
David Schull, Russo Partners
(858) 717-2310
david.schull@russopartnersllc.com
Catalyst Pharmaceuticals (NASDAQ:CPRX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Catalyst Pharmaceuticals (NASDAQ:CPRX)
Historical Stock Chart
From Jul 2023 to Jul 2024